Risperidone Should NOT Be Used for Appetite Stimulation
Risperidone (Risperdal) is not indicated for appetite stimulation and should not be used for this purpose. While the drug paradoxically causes increased appetite and weight gain as an adverse effect in psychiatric patients, this does not translate into a therapeutic indication for appetite stimulation in patients with anorexia or cachexia.
Why Risperidone Is Not Appropriate for Appetite Stimulation
FDA-Approved Indications Do Not Include Appetite Stimulation
The FDA label for risperidone 1 lists approved indications as:
- Schizophrenia (adults and adolescents)
- Bipolar mania (adults and children)
- Irritability associated with autistic disorder (children)
Appetite stimulation is nowhere mentioned as an approved use. In fact, appetite increase is listed as an adverse reaction occurring in 4-49% of pediatric patients with bipolar mania 1.
Established Guidelines Recommend Other Agents
The 2020 ASCO guideline on cancer cachexia 2 specifically addresses appetite stimulants and recommends:
- Megestrol acetate (improves appetite and body weight, though primarily adipose tissue)
- Corticosteroids (improve appetite similarly to megestrol acetate, but limited to patients with life expectancy of weeks to months due to toxicity with long-term use)
The 2003 oncology guidelines 3 similarly establish corticosteroids and synthetic progestogens as evidence-based appetite stimulants (level of evidence: B1 for corticosteroids).
Risperidone is not mentioned in either guideline as a therapeutic option for appetite stimulation.
The Mechanism Is Wrong
Research demonstrates that risperidone's effect on appetite is:
- An unwanted side effect, not a therapeutic mechanism 4, 5
- Associated with disruption of appetite-regulating hormones (insulin, leptin, bioleptin) 4
- Linked to increased appetite during oral glucose tolerance testing in children 5, but without corresponding changes in satiety hormones that would suggest a healthy appetite regulation
Animal studies show risperidone actually decreases hypothalamic neuropeptide expression (POMC, AgRP, NPY) 6, suggesting the appetite increase may be through dysregulation rather than physiologic stimulation.
Chronic Use Data Shows No Sustained Appetite Effect
In chronically treated schizophrenic patients, risperidone does not increase appetite over 5 months of treatment 7. There was actually a trend toward decreased appetite over time, and appetite changes did not correlate with weight changes. This suggests any appetite-stimulating effect is transient and not sustained with chronic use.
Significant Safety Concerns
Using risperidone for appetite stimulation would expose patients to serious risks without established benefit:
- Extrapyramidal symptoms (parkinsonism 6-27%, dystonia 2-18%, akathisia 2-10% depending on population) 1
- Metabolic dysfunction including weight gain, diabetes risk, dyslipidemia 5
- Cardiovascular effects including tachycardia and thromboembolic events
- Sedation (12-67% depending on population) 1
- Endocrine effects including hyperprolactinemia and lactation
These risks are acceptable when treating serious psychiatric conditions with established efficacy, but are not justifiable for off-label appetite stimulation when safer, evidence-based alternatives exist.
The Single Exception: Severe Feeding Disorders with Psychiatric Comorbidity
One small case series 8 described successful use of risperidone in 3 children with severe feeding disorders, failure-to-thrive, and comorbid anxiety/mood symptoms who had failed behavioral therapy. However, this represents a highly specific clinical scenario where:
- Psychiatric comorbidity was present (potentially an on-label use)
- Behavioral interventions had failed
- Medical complexity was extreme (enteral feeding required)
This does not support general use for appetite stimulation in typical cachexia or anorexia patients.
What to Use Instead
For cancer cachexia:
- First-line: Megestrol acetate 400-800 mg daily 2
- Alternative: Corticosteroids (dexamethasone 2-8 mg daily) for patients with short life expectancy 3, 2
For other causes of poor appetite: